Phospholipase A2 inhibitors

Current Opinion in Lipidology

Volumn 20, Issue 4, 2009, Pages 327-332

  Serruys, Patrick W ^a   Garcia Garcia, Hector M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Atherosclerosis; Darapladib; Inflammation; Phospholipase A2; Varespladib

Indexed keywords

(3 AMINOOXALYL 1 BENZYL 2 ETHYL 6 METHYL 1H INDOL 4 YLOXY)ACETIC ACID METHYL ESTER; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE INHIBITOR; [3 (1 BENZYL 3 CARBAMOYLMETHYL) 2 ETHYLINDOL 5 YL]OXYPROPYLPHOSPHONIC ACID; A 001; A 002; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; ESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LY 311727; LY 374388; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG; VARESPLADIB; VARESPLADIB METHYL;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETIC ACIDS; ANIMALS; ATHEROSCLEROSIS; BENZALDEHYDES; BLOOD PROTEINS; HUMANS; INDOLES; INFLAMMATION; OXIMES;

ANIMALIA;

EID: 68449103043     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832dd4c7     Document Type: Review

References (29)

1. Segers D, Garcia-Garcia HM, Cheng C, et al. A primer on the inmune system in the pathogenesis and treatment of atherosclerosis. Eurointervention 2008; 4:378-390.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-519.
4. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1275.
5. Burke AP, Farb A, Malcom GT, et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. J Am Med Assoc 1999; 281:921-926.
6. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276-1282.
7. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 2006; 1761:1246-1259.
8. 2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol 2004; 24:762-767.
9. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999; 100:1280-1284.
10. Liu PY, Li YH, Tsai WC, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003; 24:1824-1832.
11. Kugiyama K, Ota Y, Kawano H, et al. Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina. Cardiovasc Res 2000; 47:159-165.
12. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007; 27:1177-1183.
13. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338 (Pt 2):479-487.
14. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein- associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Orator Vastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113:1745-1752.
15. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111:570-575.
16. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26:1586-1593.
17. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25:923-931.
18. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523-2529.
19. Wilensky RL, Shi Y, Mohler ER 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14:1059-1066.
20. Davis B, Koster G, Douet LJ, et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 2008; 283:6428-6437.
21. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001; 505:357-363.
22. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007; 191:54-62.
23. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26:137-144.
24. Oslund RC, Cermak N, Gelb MH. Highly specific and broadly potent in hibitors of mammalian secreted phospholipases A2. J Med Chem 2008; 51:4708-4714.
25. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373:649-658.
26. Nijmeijer R, Lagrand WK, Baidoshvili A, et al. Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res 2002; 53:138-146.
27. Nijmeijer R, Lagrand WK, Visser CA, et al. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int Immunopharmacol 2001; 1:403-414.
28. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51: 1632-1641.
29. 2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118:1172-1182.